Shirley Kuhlmann Net Worth

The estimated Net Worth of Shirley R. Kuhlmann is at least $9.49 Million dollars as of 5 September 2024. Ms. Kuhlmann owns over 20,225 units of Collegium Pharmaceutical Inc stock worth over $4,314,461 and over the last 7 years she sold COLL stock worth over $3,723,317. In addition, she makes $1,449,370 as Executive Vice President, General Counsel, and Secretary at Collegium Pharmaceutical Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Kuhlmann COLL stock SEC Form 4 insiders trading

Shirley has made over 10 trades of the Collegium Pharmaceutical Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 20,225 units of COLL stock worth $773,809 on 5 September 2024.

The largest trade she's ever made was selling 38,589 units of Collegium Pharmaceutical Inc stock on 15 September 2022 worth over $697,303. On average, Shirley trades about 7,069 units every 59 days since 2018. As of 5 September 2024 she still owns at least 119,184 units of Collegium Pharmaceutical Inc stock.

You can see the complete history of Ms. Kuhlmann stock trades at the bottom of the page.

Shirley Kuhlmann biography

Shirley R. Kuhlmann serves as Executive Vice President, General Counsel, Secretary of the Company. Ms. Kuhlmann has served as our Executive Vice President and General Counsel since March 2018. Prior to joining us, Ms. Kuhlmann was a corporate and securities attorney at Pepper Hamilton LLP from September 2007 until March 2018. At Pepper Hamilton, where she was made a partner effective January 2017, Ms. Kuhlmann advised private and public companies on a range of commercial and transactional matters, including financings, corporate governance and disclosure matters, and mergers and acquisitions and other business combination transactions. Ms. Kuhlmann holds a B.A. in Economics/Political Science from Columbia University in 2004 and a J.D. from Emory University School of Law in 2007.

What is the salary of Shirley Kuhlmann?

As the Executive Vice President, General Counsel, and Secretary of Collegium Pharmaceutical Inc, the total compensation of Shirley Kuhlmann at Collegium Pharmaceutical Inc is $1,449,370. There are 4 executives at Collegium Pharmaceutical Inc getting paid more, with Joseph Ciaffoni having the highest compensation of $4,032,630.

How old is Shirley Kuhlmann?

Shirley Kuhlmann is 36, she's been the Executive Vice President, General Counsel, and Secretary of Collegium Pharmaceutical Inc since 2018. There are 19 older and no younger executives at Collegium Pharmaceutical Inc. The oldest executive at Collegium Pharmaceutical Inc is John Fallon, 72, who is the Independent Director.

What's Shirley Kuhlmann's mailing address?

Shirley's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.

Insiders trading at Collegium Pharmaceutical Inc

Over the last 10 years, insiders at Collegium Pharmaceutical Inc have traded over $80,399,308 worth of Collegium Pharmaceutical Inc stock and bought 1,112,375 units worth $13,316,951 . The most active insiders traders include Group Holdings (Sbs) Adviso..., John Gordon Freund, and David Hirsch. On average, Collegium Pharmaceutical Inc executives and independent directors trade stock every 35 days with the average trade being worth of $2,130,406. The most recent stock trade was executed by Shirley R. Kuhlmann on 5 September 2024, trading 20,225 units of COLL stock currently worth $773,809.

What does Collegium Pharmaceutical Inc do?

collegium pharmaceutical, inc. is a specialty pharmaceutical company developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. with a substantial number of patients suffering from chronic pain, collegium is committed to developing and commercializing a portfolio of products that address the growing problems associated with non-medical use, abuse and misuse of prescription products by leveraging the company’s proprietary deterx® technology platform. deterx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have a narrow therapeutic index that would benefit from protection against misuse such as breaking, crushing, grinding, or dissolving the product. the deterx technology platform is covered by u.s. and international patents and patent applications. collegium’s lead product candidate, xtampza er™, is an abuse-deterrent, ex

Complete history of Ms. Kuhlmann stock trades at Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc executives and stock owners

Collegium Pharmaceutical Inc executives and other stock owners filed with the SEC include:

• Joseph Ciaffoni,
  President, Chief Executive Officer, Director
• Scott Dreyer,
  Executive Vice President, Chief Commercial Officer
• Richard Malamut,
  Executive Vice President and Chief Medical Officer
• Paul Brannelly,
  Chief Financial Officer, Executive Vice President
• Shirley Kuhlmann,
  Executive Vice President, General Counsel, Secretary
• Alison Fleming,
  Executive Vice President, Chief Technology Officer
• Joseph J. Ciaffoni,
  Pres, CEO & Director
• Shirley R. Kuhlmann,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Richard Malamut,
  Exec. VP & Chief Medical Officer
• Michael Heffernan,
  Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Garen Bohlin,
  Independent Director
• John Fallon,
  Independent Director
• Theodore Schroeder,
  Independent Director
• John Freund,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Michael Thomas Heffernan B.S. Pharm, R.Ph.,
  Co-Founder & Chairman
• Michael Thomas Heffernan,
  Co-Founder & Chairman
• Rita Balice-Gordon,
  Director
• Scott Sudduth,
  Head of Technical Operations
• Marlo Manning,
  Head of HR
• Scott Dreyer,
  Exec. VP & Chief Commercial Officer
• Colleen Tupper,
  Exec. VP & CFO
• Jack Maroney,
  VP of Sales
• Bart J. Dunn,
  Exec. VP of Strategy & Corp. Devel.
• Alex Dasalla,
  Head of Investor Relations
• Barry S Duke,
  See remarks
• Eran Nadav,
  Director
• David Hirsch,
  Director
• Yasunori Kaneko,
  10% owner
• Venture Partners V Lp Skyli...,
  
• Capital Partners, Llc Tamme...,
  
• Thomas B Smith,
  EVP and Chief Medical Officer
• Colleen Tupper,
  EVP & Chief Financial Officer
• Patrick J Heron,
  Director
• Capital Partners, Llc Longi...,
  
• Healthcare Vi, L.P.Fhm Vi, ...,
  
• Group Holdings (Sbs) Adviso...,
  
• Venture Partners V Lp Skyli...,
  
• Neil F. Mc Farlane,
  Director